This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR]
MPT in Development
Preclinical – Early (Pre1)
Delivery Route & Method:
Intravaginal Ring (IVR)
Mechanism of Action:
Ovulation inhibition (pregnancy); binding to HIV envelope glycoproteins to prevent entry of HIV into target cells (QGRFT).
Oak Crest Institute of Science
Nat. Institute Allergy & Infect. Diseases (NIAID)
National Institutes of Health (NIH)
NIH: R01 (NIAID)
Description: A 90-day pod-type MPT IVR for pregnancy and HIV prevention that could reduce both the emergence of ARV-resistant HIV and the concern of potential increased risk of HIV transmission associated with use of progestin-only products.
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.